ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE

Clinical trials for ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE explained in plain language.

Never miss a new study

Get alerted when new ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE trials appear

Sign up with your email to follow new studies for ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Extended treatment trial for rare immune disease seeks to prove long-term safety

Disease control Terminated

This study provided long-term treatment with the drug CDZ173 to patients with APDS/PASLI, a rare genetic immune disorder. The research followed 37 patients who had previously participated in related studies to monitor the drug's safety and effectiveness over time. The goal was to…

Matched conditions: ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE

Phase: PHASE2, PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control

Last updated Apr 04, 2026 08:50 UTC

ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE

Get alerted when new ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE trials appear

Extended treatment trial for rare immune disease seeks to prove long-term safety